UY25950A1 - Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea - Google Patents
Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion oseaInfo
- Publication number
- UY25950A1 UY25950A1 UY25950A UY25950A UY25950A1 UY 25950 A1 UY25950 A1 UY 25950A1 UY 25950 A UY25950 A UY 25950A UY 25950 A UY25950 A UY 25950A UY 25950 A1 UY25950 A1 UY 25950A1
- Authority
- UY
- Uruguay
- Prior art keywords
- same
- treatment
- prevention
- resorption
- oral
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 8
- 230000002265 prevention Effects 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000006386 Bone Resorption Diseases 0.000 title abstract 2
- 230000024279 bone resorption Effects 0.000 title abstract 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 abstract 4
- 230000002159 abnormal effect Effects 0.000 abstract 4
- 229940122361 Bisphosphonate Drugs 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 229940062527 alendronate Drugs 0.000 abstract 2
- 229960004343 alendronic acid Drugs 0.000 abstract 2
- 150000004663 bisphosphonates Chemical class 0.000 abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Saccharide Compounds (AREA)
- Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
- Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
- Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
Abstract
METODO PARA EL TRATAMIENTO DE LA RESORCION OSEA ANORMAL EN UN MAMIFERO QUE REQUIERA DICHO TRATAMIENTO, MINIMIZANDO LA PRESENTACION DE EFECTOS GASTROINTESTINALES ADVERSOS, EL REFERIDO METODO COMPRENDE LA ADMINISTRACION ORAL EN DICHO MAMIFERO DE UNA CANTIDAD FARMACEUTICAMENTE EFECTIVA DEL BISFOSFONATO COMO UNIDAD DE DOSIFICACION, ACORDE CON UN ESQUEMA CONTINUO CON INTERVALOS ENTRE DOSIS QUE SE SELECCIONAN DEL GRUPO QUE CONSISTE EN UNA DOSIFICACION SEMANAL, DOS DOSIFICACIONES SEMANALES, UNA DOSIFICACION BISEMANAL Y DOS DOSIFICACIONES MENSUALES. ESTE ESQUEMA CONTINUO SE MANTIENE HASTA QUE SE LOGRA EL EFECTO TERAPEUTICO DESEADO EN DICHO MAMIFERO. EN OTRAS REALIZACIONES DE LA INVENCION, LA MISMA SE REFIERE A UN METODO ORAL PARA LA PREVENCION DE LA RESORCION OSEA ANORMAL EN UN MAMIFERO EN OTRAS REALIZACIONES DE LA INVENCION, LA MISMA SE REFIERE A UN METODO ORAL PARA LA PREVENCION O EL TRATAMIENTO DE LA RESORCION OSEA ANORMAL EN UN SER HUMANO. EN OTRAS REALIZACIONES DE LA INVENCION, LA MISMA SE REFIERE A UN METODO ORAL PARA LA PREVENCION O EL TRATAMIENTO DE LA OSTEOPOROSIS EN UN MAMIFERO; A UN METODO ORAL PARA LA PREVENCION O EL TRATAMIENTO DE LA RESORCION OSEA ANORMAL EN UN SER HUMANO QUE REQUIERA DICHO TRATAMIENTO, COMPRENDIENDO LA ADMINISTRACION A DICHO SER HUMANO DE ENTRE APROXIMADAMENTE 8,75 MG Y APROXIMADAMENTE 140 MG. EN BASE A ACIDO ALENDRONICO ACTIVO, DE UN BISFOSFONATO SELECCIONADO DE UN GRUPO CONSISTENTE EN ALENDRONATO, SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO Y MEZCLAS DE LOS MISMOS. EN OTRAS REALIZACIONES DE LA INVENCION, LA MISMA SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE ENTRE APROXIMADAMENTE L40 MG. EN BASE A ACIDO ALENDRONICO ACTIVO, DE UN BISFOSFONATO SELECCIONADO DE UN GRUPO CONSISTENTE EN ALENDRONATO, SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO Y MEZCLAS DE LOS MISMOS. TODOS LOS PORCENTAJES Y LAS RELACIONES UTILIZADAS EN EL PRESENTE SE REFIEREN A PESO EXCEPTO EN LOS CASOS EN QUE SE INDIQUE OTRA COSA. ESTA INVENCION PUEDE COMPRENDER LOS INGREDIENTES, COMPONENTES Y METODOS ESENCIALES Y OPCIONALES AQUÍ DESCRITOS, PUEDE CONSISTIR EN LOS MISMOS O PUEDE CONSISTIR ESENCIALMENTE EN LOS MISMOS
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5335197P | 1997-07-22 | 1997-07-22 | |
US5353597P | 1997-07-23 | 1997-07-23 | |
GBGB9717590.5A GB9717590D0 (en) | 1997-08-20 | 1997-08-20 | Oral method for treating or preventing abnormal bone resorption |
GBGB9717850.3A GB9717850D0 (en) | 1997-08-22 | 1997-08-22 | Oral method for treating or preventing abnormal bone resorption |
Publications (1)
Publication Number | Publication Date |
---|---|
UY25950A1 true UY25950A1 (es) | 2000-09-29 |
Family
ID=27451690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY25950A UY25950A1 (es) | 1997-07-22 | 2000-01-17 | Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea |
Country Status (31)
Country | Link |
---|---|
EP (5) | EP1175903A3 (es) |
JP (2) | JP3479780B2 (es) |
KR (3) | KR100391732B1 (es) |
CN (3) | CN1166365C (es) |
AT (2) | ATE209037T1 (es) |
AU (1) | AU8493698A (es) |
BG (1) | BG66282B1 (es) |
BR (1) | BR9810779A (es) |
CA (1) | CA2294595C (es) |
CY (2) | CY1107535T1 (es) |
DE (6) | DE69803291T2 (es) |
DK (2) | DK1175904T3 (es) |
EA (1) | EA004544B2 (es) |
EE (1) | EE05603B1 (es) |
ES (3) | ES2164447T3 (es) |
HK (4) | HK1042230A1 (es) |
ID (1) | ID24096A (es) |
IL (1) | IL133535A0 (es) |
IS (3) | IS5315A (es) |
LU (2) | LU91222I2 (es) |
NL (2) | NL300223I1 (es) |
NO (1) | NO20000323L (es) |
NZ (1) | NZ501807A (es) |
PL (1) | PL195272B1 (es) |
PT (2) | PT1175904E (es) |
SG (2) | SG109478A1 (es) |
SI (1) | SI0998292T1 (es) |
SK (1) | SK932000A3 (es) |
TR (1) | TR200000145T2 (es) |
UY (1) | UY25950A1 (es) |
WO (1) | WO1999004773A2 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE263566T1 (de) | 1998-12-25 | 2004-04-15 | Yamanouchi Pharma Co Ltd | Medizinische zusammensetzungen zur behandlung von knochenschäden im multiplen myelom |
WO2000071104A2 (en) * | 1999-05-21 | 2000-11-30 | Novartis Ag | Use of bisphosphonic acids for treating angiogenesis |
EP1114642B1 (en) * | 1999-07-19 | 2010-01-06 | Toray Industries, Inc. | Drugs for periodontal diseases |
AU2270101A (en) * | 1999-12-20 | 2001-07-03 | Merck & Co., Inc. | Pharmaceutical kit |
AU2580001A (en) | 1999-12-20 | 2001-07-03 | Merck & Co., Inc. | Blister package for pharmaceutical treatment card |
MXPA02009924A (es) * | 2000-04-07 | 2004-08-19 | Univ Texas | Composiones unicas de fosfolipidos de ion anfoterico y bisfosfonatos y uso de las composiciones como sistemas de suministro de bisfosfato con toxicidad gi reducida. |
DK1591122T3 (da) * | 2000-06-20 | 2013-02-25 | Novartis Ag | Fremgangsmåde til indgivelse af bisphosphonater |
WO2001097788A2 (en) | 2000-06-20 | 2001-12-27 | Novartis Ag | Method of administering bisphosphonates |
US6638920B2 (en) * | 2000-07-21 | 2003-10-28 | Merck & Co., Inc. | Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses |
SE0101379D0 (sv) * | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
PT1392325E (pt) * | 2001-05-02 | 2006-10-31 | Novartis Ag | Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose |
EP1506041B1 (en) | 2002-05-10 | 2007-10-24 | F. Hoffmann-La Roche Ag | Ibandronic acid for the treatment and prevention of osteoporosis |
SE0203065D0 (sv) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
MXPA06003063A (es) * | 2003-09-19 | 2006-05-31 | Pfizer Prod Inc | Composiciones farmaceuticas y metodos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina- d y un bisfosfonato. |
WO2005072747A1 (ja) * | 2004-02-02 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | 骨吸収抑制剤 |
AU2006290519B2 (en) * | 2005-09-16 | 2012-10-18 | Selamine Ltd | Bisphosphonate formulation |
CN103140220A (zh) * | 2010-12-06 | 2013-06-05 | 给药技术公司 | 具有快速溶解特性的稳定的泡腾双磷酸盐制剂 |
CN106924257B (zh) * | 2017-03-14 | 2019-11-19 | 湖南赛隆药业有限公司 | 质子泵抑制剂和抗骨质疏松药的复合物及其用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL84731A0 (en) * | 1986-12-19 | 1988-05-31 | Norwich Eaton Pharma | Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them |
SE8704436D0 (sv) * | 1987-11-13 | 1987-11-13 | Pm Konsult Handelsbolag | Anvendning av antisekretoriska substanser for nya indikationer |
ATE122228T1 (de) * | 1991-07-01 | 1995-05-15 | Gergely Gerhard | Verfahren zur herstellung einer pharmazeutischen zubereitung mit wenigstens zwei verschiedenen wirkstoffen und verwendung einer solchen zubereitung. |
DE69231313T2 (de) * | 1991-11-22 | 2001-03-15 | Procter & Gamble Pharmaceuticals, Inc. | Risedronat enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe |
US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
US5294433A (en) * | 1992-04-15 | 1994-03-15 | The Procter & Gamble Company | Use of H-2 antagonists for treatment of gingivitis |
DE69316013T2 (de) * | 1992-06-30 | 1998-07-09 | Procter & Gamble Pharma | Verwendung von phosphinate zur behandlung der osteoporose |
US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
US5646134A (en) * | 1994-04-21 | 1997-07-08 | Merck & Co., Inc. | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
EP0831843A1 (en) * | 1995-06-06 | 1998-04-01 | Merck & Co., Inc. | Bisphosphonate therapy for bone loss associated with rheumatoid arthritis |
DE69726879T2 (de) * | 1996-05-17 | 2004-10-14 | Merck & Co., Inc. | Biphosphonat-formulierung mit brausewirkung |
-
1998
- 1998-07-17 SI SI9830086T patent/SI0998292T1/xx unknown
- 1998-07-17 KR KR1020007000680A patent/KR100391732B1/ko not_active Expired - Fee Related
- 1998-07-17 DE DE69803291T patent/DE69803291T2/de not_active Revoked
- 1998-07-17 WO PCT/US1998/014796 patent/WO1999004773A2/en active Application Filing
- 1998-07-17 PL PL98338635A patent/PL195272B1/pl unknown
- 1998-07-17 KR KR1020027013594A patent/KR20030097610A/ko not_active Ceased
- 1998-07-17 SG SG200107221A patent/SG109478A1/en unknown
- 1998-07-17 ES ES98935752T patent/ES2164447T3/es not_active Expired - Lifetime
- 1998-07-17 DE DE1998603291 patent/DE122006000009I1/de active Pending
- 1998-07-17 DE DE69837450T patent/DE69837450T2/de not_active Expired - Lifetime
- 1998-07-17 DK DK01201913T patent/DK1175904T3/da active
- 1998-07-17 EP EP01201912A patent/EP1175903A3/en not_active Ceased
- 1998-07-17 DE DE200712000063 patent/DE122007000063I1/de active Pending
- 1998-07-17 KR KR1020027013595A patent/KR20030097611A/ko not_active Ceased
- 1998-07-17 BR BR9810779-8A patent/BR9810779A/pt not_active Application Discontinuation
- 1998-07-17 AT AT98935752T patent/ATE209037T1/de active
- 1998-07-17 CN CNB988074737A patent/CN1166365C/zh not_active Ceased
- 1998-07-17 ES ES01201913T patent/ES2269014T3/es not_active Expired - Lifetime
- 1998-07-17 CN CNB2004100557350A patent/CN1299689C/zh not_active Expired - Lifetime
- 1998-07-17 DK DK98935752T patent/DK0998292T3/da active
- 1998-07-17 PT PT01201913T patent/PT1175904E/pt unknown
- 1998-07-17 EP EP01201910A patent/EP1132088A3/en not_active Ceased
- 1998-07-17 NZ NZ501807A patent/NZ501807A/en not_active IP Right Cessation
- 1998-07-17 DE DE01201911T patent/DE01201911T1/de active Pending
- 1998-07-17 SG SG200603406-0A patent/SG139556A1/en unknown
- 1998-07-17 EP EP98935752A patent/EP0998292B1/en not_active Revoked
- 1998-07-17 CN CNA2004100557346A patent/CN1602879A/zh active Pending
- 1998-07-17 EA EA200000151A patent/EA004544B2/ru not_active IP Right Cessation
- 1998-07-17 AU AU84936/98A patent/AU8493698A/en not_active Abandoned
- 1998-07-17 ID IDW20000114A patent/ID24096A/id unknown
- 1998-07-17 DE DE01201913T patent/DE01201913T1/de active Pending
- 1998-07-17 IL IL13353598A patent/IL133535A0/xx unknown
- 1998-07-17 ES ES01201910T patent/ES2253136T1/es active Pending
- 1998-07-17 PT PT98935752T patent/PT998292E/pt unknown
- 1998-07-17 EP EP01201913A patent/EP1175904B8/en not_active Revoked
- 1998-07-17 JP JP50991499A patent/JP3479780B2/ja not_active Expired - Lifetime
- 1998-07-17 EP EP01201911A patent/EP1151752A3/en not_active Ceased
- 1998-07-17 AT AT01201913T patent/ATE357921T1/de active
- 1998-07-17 TR TR2000/00145T patent/TR200000145T2/xx unknown
- 1998-07-17 CA CA002294595A patent/CA2294595C/en not_active Expired - Fee Related
- 1998-07-17 SK SK93-2000A patent/SK932000A3/sk not_active Application Discontinuation
- 1998-07-17 EE EEP200000040A patent/EE05603B1/xx unknown
-
1999
- 1999-12-21 IS IS5315A patent/IS5315A/is unknown
-
2000
- 2000-01-17 UY UY25950A patent/UY25950A1/es not_active Application Discontinuation
- 2000-01-18 BG BG104093A patent/BG66282B1/bg unknown
- 2000-01-21 NO NO20000323A patent/NO20000323L/no unknown
-
2002
- 2002-03-04 HK HK02101656.1A patent/HK1042230A1/en unknown
- 2002-03-12 HK HK02101869.4A patent/HK1042232A1/en unknown
- 2002-03-16 HK HK02102042.2A patent/HK1040494A1/en unknown
- 2002-03-16 HK HK02102043.1A patent/HK1040495A1/en unknown
-
2003
- 2003-03-10 JP JP2003063378A patent/JP2005068010A/ja active Pending
-
2004
- 2004-04-21 IS IS7231A patent/IS7231A/is unknown
- 2004-04-21 IS IS7230A patent/IS7230A/is unknown
-
2006
- 2006-02-07 NL NL300223C patent/NL300223I1/nl unknown
- 2006-02-15 LU LU91222C patent/LU91222I2/fr unknown
-
2007
- 2007-03-29 CY CY20071100442T patent/CY1107535T1/el unknown
- 2007-09-12 LU LU91364C patent/LU91364I2/fr unknown
- 2007-09-13 NL NL300292C patent/NL300292I1/nl unknown
- 2007-09-20 CY CY2007022C patent/CY2007022I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY25950A1 (es) | Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea | |
US5853759A (en) | Effervescent alendronate formulation | |
CA2254060C (en) | Effervescent bisphosphonate formulation | |
ES2247123T7 (es) | Método para administrar bisfosfonatos | |
RU94046316A (ru) | Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза | |
YU31795A (sh) | Oralne tečne formulacije alendronata | |
JPH08505142A (ja) | 骨損失を治療及び予防するためのビスホスホネート/エストロゲン療法 | |
RU2008103617A (ru) | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза | |
DK0833643T3 (da) | Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme | |
RU94045950A (ru) | Фармацевтический препарат и способ его приготовления | |
AR037560A1 (es) | Formulacion de altas dosis de ibandronato | |
KR970061249A (ko) | 골다공증을 치료 또는 방지하기 위한 조성물 | |
MX9303243A (es) | Compuestos de fosfonato novedosos que contienen nitrogeno cuaternario, composiciones farmaceuticas y metodos para tratar el metabolismo anormal del calcio y el fosfato, y metodos para tratar y prevenir calculos dentales y placa dental. | |
McClung | Bisphosphonates | |
ES2060708T3 (es) | Sistema terapeutico de liberacion retardada para formulaciones farmaceuticas liquidas. | |
AR013994A1 (es) | Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes. | |
US6399592B1 (en) | Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss | |
ES2215856T3 (es) | Solucion de sal monosodica tetrahidrato de n-(o-(p-pivaloiloxibenceno-sulfonilamino)benzoil)glicina y medicamento que contiene esta solucion. | |
ES2182504T3 (es) | Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento. | |
ES2139013T3 (es) | Compuestos de fosfonato que contienen nitrogeno cuaternario para tratar el metabolismo anormal del calcio y fosfato. | |
US20060034921A1 (en) | Effervescent bisphosphonate formulation | |
US20040137058A1 (en) | Effervescent bisphosphonate formulation | |
US20070087052A1 (en) | Effervescent bisphosphonate formulation | |
AR013500A1 (es) | Uso de acido alendronico o una sal farmaceuticamente aceptable del mismo o una mezcal de los mismos para la manufactura de un medicamento | |
Moradi et al. | Evaluation of Jaw Osteonecrosis Following Intra-Ligament Anesthesia in Zoledronate-Treated Rats: a Histological Evaluation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RDES | Application refused |
Effective date: 20041115 |